newsfilter
← Latest News
Business Wire·

RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering

RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the pricing of its upsized $311 million initial public